Intech Biopharm Ltd (TWO:6461) — Market Cap & Net Worth
Market Cap & Net Worth: Intech Biopharm Ltd (6461)
Intech Biopharm Ltd (TWO:6461) has a market capitalization of $88.22 Million (NT$2.80 Billion) as of August 3, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19568 globally and #1109 in its home market, demonstrating a -1.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intech Biopharm Ltd's stock price NT$15.70 by its total outstanding shares 178351761 (178.35 Million). Review 6461 total liabilities to assess the company's total debt and financial obligations.
Intech Biopharm Ltd Market Cap History: 2015 to 2026
Intech Biopharm Ltd's market capitalization history from 2015 to 2026. Data shows change from $271.69 Million to $88.22 Million (-8.06% CAGR).
Intech Biopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intech Biopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.93x
Intech Biopharm Ltd's market cap is 0.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $233.65 Million | $16.61 Million | -$239.31 Million | 14.07x | N/A |
| 2018 | $105.48 Million | $17.23 Million | -$222.07 Million | 6.12x | N/A |
| 2019 | $103.39 Million | $16.68 Million | -$311.42 Million | 6.20x | N/A |
| 2020 | $116.31 Million | $21.11 Million | -$250.37 Million | 5.51x | N/A |
| 2021 | $112.38 Million | $38.90 Million | -$301.76 Million | 2.89x | N/A |
| 2022 | $186.83 Million | $23.65 Million | -$327.88 Million | 7.90x | N/A |
| 2023 | $168.01 Million | $25.85 Million | -$337.99 Million | 6.50x | N/A |
| 2024 | $148.34 Million | $39.78 Million | -$368.21 Million | 3.73x | N/A |
| 2025 | $100.02 Million | $107.53 Million | -$389.03 Million | 0.93x | N/A |
Competitor Companies of 6461 by Market Capitalization
Companies near Intech Biopharm Ltd in the global market cap rankings as of August 3, 2026.
Key companies related to Intech Biopharm Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Intech Biopharm Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Intech Biopharm Ltd's market cap moved from $271.69 Million to $ 88.22 Million, with a yearly change of -8.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$88.22 Million | -11.80% |
| 2025 | NT$100.02 Million | -32.58% |
| 2024 | NT$148.34 Million | -11.71% |
| 2023 | NT$168.01 Million | -10.08% |
| 2022 | NT$186.83 Million | +66.25% |
| 2021 | NT$112.38 Million | -3.38% |
| 2020 | NT$116.31 Million | +12.50% |
| 2019 | NT$103.39 Million | -1.98% |
| 2018 | NT$105.48 Million | -54.86% |
| 2017 | NT$233.65 Million | +20.67% |
| 2016 | NT$193.62 Million | -28.73% |
| 2015 | NT$271.69 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Intech Biopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $88.22 Million USD |
| MoneyControl | $88.22 Million USD |
| MarketWatch | $88.22 Million USD |
| marketcap.company | $88.22 Million USD |
| Reuters | $88.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more